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Abstract
MKT-077, a rhodacyanine dye, was shown to produce cancer specific cell death. However, complications prevented the use
of this compound beyond clinical trials. Here we describe YM-1, a derivative of MKT-077. We found that YM-1 was more
cytotoxic and localized differently than MKT-077. YM-1 demonstrated this cytotoxicity across multiple cancer cell lines. This
toxicity was limited to cancer cell lines; immortalized cell models were unaffected. Brief applications of YM-1 were found to
be non-toxic. Brief treatment with YM-1 restored tamoxifen sensitivity to a refractory tamoxifen-resistant MCF7 cell model.
This effect is potentially due to altered estrogen receptor alpha phosphorylation, an outcome precipitated by selective
reductions in Akt levels (Akt/PKB). Thus, modifications to the rhodocyanine scaffold could potentially be made to improve
efficacy and pharmacokinetic properties. Moreover, the impact on tamoxifen sensitivity could be a new utility for this
compound family.
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Introduction
MKT-077, a cationic rhodacyanine, has demonstrated cancer
specific toxicity and growth inhibition in vitro and in vivo across
multiple cancer varieties [1]. It was determined that MKT-077
localized to the mitochondria [1]. MKT-077 entered into clinical
trials for the treatment of advanced and refractory solid tumors of
various cellular origin, including: kidney, lung, prostate, colon,
adenocarcinomas, and melanomas [2,3]. The primary negative
side effect observed in both studies was renal toxicity [2,3]. The
observed toxicity halted recruitment to one trial as similar animal
studies showed irreversible renal toxicity following administration
of MKT-077 [2,3]. Later it was discovered that MKT-077
interacted with mortalin (mot-2), a 70-kda heat shock protein
(Hsp70) family member, and that the interaction of MKT-077
with mot-2 induced the release of the tumor suppressor p53 from a
complex with mot-2 [4]. This mot-2/p53 complex inactivated the
tumor suppression abilities of p53 by sequestering it in the cytosol
in vivo [5].
Breast cancers are among the most common cancers diagnosed
in women [6]. Published data states that treating MCF7 cells, a
breast cancer cell model, with MKT-077 produces cytotoxicity
and alters growth [1,2]. However, in the results of two published
Phase I clinical trials, no patients with a solid breast tumor or
refractory breast tumor were included in the study [2,3]. Though
there are numerous breast cancer chemotherapies, resistance to
breast cancer therapies can arise in roughly 30% of women treated
for breast cancer [7]. Known resistances in breast cancers have
been observed for not only standard anti-cancer strategies, such as
doxorubicin, but also trastuzumab and tamoxifen (4-OHT)
[8,9,10].
Breast cancers also have a high prevalence of mutations;
mutations which can promote tumorigenesis and survival [11].
While these mutations produce targets for treatments, other
mutations can overcome signaling cascade network circuitry to
eliminate upstream targets [12,13]. This reduces the number of
potential targets, reducing the cadre of treatment options, and
increasing the potential for resistance genesis. In addition,
resistance can emerge when regulatory proteins are altered to
allow pro-survival proteins to act unabated. Several kinases related
to cell survival have been implicated in facilitating chemotherapy
resistance [14,15,16,17,18]. For example, phosphorylation of the
estrogen receptor alpha (ERa) causes ERa to become active
regardless of estrogen binding, resulting in resistance to 4-OHT.
Thus, strategies to re-sensitize refractory cancer cells to existing
therapies are sorely needed.
In these data, we identify a functional derivative of MKT-077
that showed increased cytotoxicity across multiple cancer varieties
while still retaining the cancer specificity associated with MKT-
077. This enhanced activity was due to the intracellular
localization of the compound. In addition, short treatments with
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resistance to the ERa antagonist, tamoxifen. One way in which
these compounds are working is by reducing total Akt levels, which
can contribute to ERa insensitivity to tamoxifen. Combined, the
rhodacyanine scaffold holds great potential as a cancer therapeutic
both as an individual treatment strategy but also, potentially, as a
combinational or synergistic option for use with existing regimens.
Methods
Cell Lines
Tamoxifen resistant (TR-MCF7) and parental MCF7 cells were
generously provided by Dr. Jin Q. Cheng of Moffitt Cancer
Center (Tampa, FL). The MCF7 line was originally generated by
the Michigan Cancer Foundation and were obtained from ATCC
(Manassas, VA) and the TR-resistance was produced by chronic
low dose treatment with tamoxifen. HEK-293, M17, H4, MDA-
MB-231, Hs578T and NIH-3T3 cells were purchased from
ATCC (Manassas, VA). HeLa cells were generously provided by
Dr. Kenneth E. Ugen at the University of South Florida. He
originally obtained them from ATCC (Manassas, VA). These cells
were generated from a cervical tumor from Henrietta Lacks.
Chemicals and Antibodies
Methylene blue (MB) was purchased from Sigma Aldrich (St.
Louis, MO). MKT-077 and YM-1 were synthesized as described
[19]. Anti-Akt1, Akt2, and pAktS473 were purchased from Cell
Signaling Technology (Danvers, MA). Anti-ERa, and pERa S167
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Anti-Actin was purchased from Sigma Aldrich. Anti-GAPDH was
purchased from Meridian Life Science (Memphis, TN).
Cell Culture and Drug Treatments
MCF7, MDA-MB-231, Hs578T and HeLa cells were grown as
previously described [20]. H4 and HEK-293 cells were cultured in
OPTI - modified Eagle’s medium (OPTI-MEM) from Invitrogen
supplemented with 10% fetal bovine serum (FBS) and 1%
PenStrep (Invitrogen). M17 cells were cultured in OPTI-MEM
supplemented with 10% FBS, 1% PenStrep and 100 mg/L
Sodium Pyruvate. NIH-3T3 cells were cultured in DMEM with
low-sodium bicarbonate (1.5 g/L) from ATCC supplemented with
10% FBS and 1% PenStrep. TR-MCF7 cells were grown in
DMEM (described with MCF7 cells) supplemented with 10 mM4 -
OHT. MKT-077 and YM-1 were dissolved in DMSO. DMSO
was used as vehicle for MKT-077 and YM-1 where indicated.
Exact treatment strategies accompany data in results section.
Protein Collection, Quantitation, and Western Blotting
Cells were harvested by application of mammalian protein
extraction reagent (Thermo) as previously described [20]. Protein
level measurement, equilibration, western blotting, and detection
were performed as previously described [20].
Lactate Dehydrogenase (LDH) Assay
Indicated cell lines were plated in designated medium. Once
cells reached ,95% confluency, MKT-077 or YM-1 was applied
in DMEM without phenol red. After times indicated per
experiment, medium was collected from each treatment and
centrifuged to pellet dead cells and debris. Protocol was followed
as supplied from Cytotox-96 kit (Promega).
Mitochondrial Isolation and Spectroscopy
MCF7 cells were treated for 6 hours with vehicle (DMSO), MB,
YM-1, or MKT-077. Following treatment cells were harvested
and subcellular fractions collected using Pierce Mitochondrial
Isolation Kit from Thermo Scientific (Rockford, IL). Analysis of
drug localization was performed by spectroscopy on Thermo
Scientific Nanodrop spectrophotometer. Concentrations and
subsequent percentages were approximated by generated concen-
tration:absorbance curve (not shown).
MTT Cell Viability Assay
TR-MCF7 cells were plated in a 96well plate in medium
containing 10 mM 4-OHT. When cells reached ,90% confluency
cells were treated in OPTI-MEM in one of four conditions 1:
10 mM 4-OHT in OPTI-MEM for the full 48 h of experiment. 2:
YM-1 (or vehicle) at indicated concentrations for 4 hours followed
by exchange of YM-1 medium with medium containing 10 mM4 -
OHT. 3: YM-1 (or vehicle) at indicated concentrations for 4 hours
followed by exchange of YM-1 medium with medium containing
95% EtOH (vehicle for 4-OHT). Or, 4: YM-1 (or vehicle) at
indicated concentrations for the full 48 hours of experiment. MTT
assay kit was purchased from ATCC and assay was run as per
supplied protocol.
Isolation of Nuclear Proteins
TR-MCF7 cells were grown in designated medium in 10 cm
dishes. Cells were treated for 4 h with 10 mM 4-OHT, 10 mM
YM-1, both or vehicle(s) for both compounds. Following
incubation, cells were harvested and nuclear proteins isolated
using reagents and supplied protocol from the Qproteome Nuclear
Protein Kit (Qiagen).
Results
The cytotoxicity profiles of a series of derivatives to MKT-077
on MCF7 cells were compared in a small-scale screen. The
derivative YM-1 was the only compound found to have dose
dependently higher toxicity than MKT-077 after 24 hours (LDH
values normalized for cell number)(Figure 1A). One possible
reason for this improved potency was cellular localization. Taking
advantage of the unique spectral properties of these compounds,
MCF7 cells were treated with MKT-077 or YM-1 and cellular
separation of mitochondria and cytosol were performed. Methy-
lene blue, a compound known to localize to the mitochondria, was
used as a control [21]. The subcellular fractions were analyzed
spectrophotometrically. These values were compared with a
generated standard curve of Abs:concentration (data not shown)
to give an approximate concentration of compound in each
fraction and thus a percentage of drug per location. Interestingly,
YM-1, unlike MKT-077 was more prevalent in the cytosolic
fractions (Figure 1B).
Concerned that the lack of mitochondrial interaction would
reduce the cytotoxic specificity seen with rhodacyanine’s for
cancer cells, the selectivity of YM-1 on several cancer and
immortalized cells lines were tested. These included: MCF7,
Hs578T and MDA-MB-231 (breast cancer), M17 (neuroblasto-
ma), H4 (neuroglioma), HeLa (cervical cancer), and two
immortalized cell lines: HEK 293 (human embryonic kidney)
and NIH 3T3 (murine fibroblast). Robust cytotoxicity (1323% of
vehicle), as measured by lactate dehydrogenase (LDH) assay, was
observed in MCF7 cells following 24-hour YM-1 treatment
(Figure 2A). As expected, these toxicity values were higher than
those observed in Figure 1A since we used a larger cell population
(1A<0.2610
6 cells; 2A<1.2610
6 cells) and thus more LDH was
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tested all displayed toxicity following YM-1 administration;
whereas, the two immortalized cell lines displayed minimal to no
toxicity by LDH assay (Figure 2B). This demonstrated that the
cytosolic localization of YM-1 did not affect its specificity for
cancer cells.
YM-1 efficacy was then tested in a cell model of tamoxifen-
resistance. The toxicity of YM-1 in a refractory tamoxifen (4-
OHT) resistant MCF7 (TR-MCF7) cell line was compared to that
of the parental MCF7 (non-resistant) cell line. Indeed, YM-1
effectively killed both standard and resistant (TR-MCF7) cells after
48-hour incubation (Figure 3A). Given the previous concerns
with chronic MKT-077 treatment, we speculated that a shorter
treatment with YM-1 might be equally toxic. To test this, MCF7
cells and TR-MCF7 cells were treated with 10 mM YM-1 for
4 hours. This was removed and replaced with vehicle for
44 hours. In addition, TR-MCF7 cells were treated with either
4-OHT or the vehicle for 4-OHT (95% EtOH) (Figure 3B). In
each case, minimal toxicity was observed.
Cell viability (MTT) assays were then used to test whether this
shorter treatment strategy was affecting cell proliferation. The TR-
MCF7 cells were grown in media containing 10 mM 4-OHT. Our
designed treatment strategy contained four conditions all termi-
nating at 48 hours: 1. 10 mM 4-OHT alone for 48 hours, 2. YM-1
(or vehicle) treatment for 4 hours followed by re-addition of
10 mM 4-OHT for 44 hours, 3. YM-1 (or vehicle) treatment for
4 hours followed by 95% EtOH (vehicle for 4-OHT), and 4. YM-1
(or vehicle) treatment for the full 48-hours. MTT assays revealed
that the 4-hour 10 mM YM-1 followed by 10 mM 4-OHT
treatment reduced viability by 60% relative to the 4-OHT
treatment alone. The 10 mM YM-1 followed by 95% EtOH
treatment did not alter viability (Figure 4A). The 48-hour 10 mM
YM-1 treatment reduced viability by 40% compared to 48-hour 4-
OHT treatment, similar to Figure 3A.
All treatment strategies containing YM-1 were analyzed by two-
way ANOVA (Figure 4B). This analysis revealed a significant
effect by treatment strategy and concentration of YM1 (F(4,
30)=41.04, p,0.0001), (F(2,30)=54.22, p,0.0001). The interac-
tion between treatment strategy and concentration was not
significant (F(8,30)=1.83, p=0.1107). Bonferroni post-hoc anal-
ysis of this 2-way ANOVA showed no significant differences
between any of the concentrations used for the 48-hour YM-1
Figure 1. MKT-077 derivative, YM-1, shows enhanced toxicity and altered localization. MCF7 cells were treated for 24 hours with three
concentrations of MKT-077 or YM-1. After 24 hours, medium was collected and analyzed by LDH assay. Values shown are a % of vehicle treatment 6
SD (A). MCF7 cells were treated with MKT-077, YM-1 or methylene blue (MB). Mitochondrial fractions were collected and compound location was
measured by spectrophotometer (B).
doi:10.1371/journal.pone.0035566.g001
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(all p.0.05); whereas, all the concentrations used for the 4-hour
YM-1 followed by 4-OHT treatment were significantly different
from the 4-hour YM-1 followed by 95% EtOH treatment (all
p,0.05). All the concentrations of the 4-hour YM-1 followed by 4-
OHT and the 48-hour YM-1 were significantly different (all
p,0.05) with the exception of the 10 mM YM-1 concentration
(p.0.05). We attributed the lack of significance to the general
toxicity caused by the 48-hour 10 mM concentration of YM-1 (see
Figure 3A & B). A one-way ANOVA of the YM-1 concentration
curve for the 4 hour YM-1 treatment followed by 44 hours of 4-
OHT treatment revealed that the 10 mM concentration was
significantly different from all other concentrations
(F(4,10)=16.49, p=0.0002)(Figure 4C). The concentration
curve for the 4 hour YM-1 treatment followed by 95% EtOH
treatment displayed that no concentration was significant from any
other concentration by one-way ANOVA (F(4,10)=3.435,
p=0.0516)(Figure 4D). Comparison of all of the 48 hour YM-
1 concentrations, by one-way ANOVA, displayed that, again, the
10 mM concentration was significantly different from all other
concentrations in this treatment (F(4,10)=12.32,
p=0.0007)(Figure 4E). We continued our analysis by comparing
the 10 mM YM-1 concentration, from all treatment groups, with
the null treatment. Viability values of all aforementioned
Figure 2. YM-1 toxicity specific to cancer cells; non-cancer cells
unaffected. MCF7 cells (breast cancer) were treated for 24 hours with
increasing concentrations of YM-1. After 24 hours, medium was
collected and analyzed by LDH cytotoxicity assay. Values shown are a
% of vehicle treatment 6 SD (A). Hs578T and MDA-MB-231 (breast
cancer), M17 (neuroblastoma), H4 (neuroglioma), and HeLa (cervical
cancer) cell treated with increasing concentrations of YM-1 and the
toxicity was compared to NIH-3T3 (mouse embryonic fibroblast) and
HEK 293 (human embryonic kidney) cells for cancer specific toxicity. All
cell lines were treated for 24 hours. After 24 hours, media were
collected and analyzed by LDH assay. Values shown are a % of vehicle
treatment 6 SD (B).
doi:10.1371/journal.pone.0035566.g002
Figure 3. TR-MCF7 cells and MCF7 cells susceptible to YM-1
toxicity at 48 hours but not at 4 hours; tamoxifen does not
alter cytotoxicity. TR-MCF7 and parental MCF7 cells were treated for
48 hours in with 10 mM YM-1. After 48 hours, media were collected and
analyzed by LDH assay. Values shown are a % of vehicle treatment 6 SD
(A). MCF7 cells were treated for 4 hours with 10 mM YM-1. At 4 hours,
medium was replaced with standard growth media for 44 hours. TR-
MCF7 cells were treated with 10 mM YM-1 for 4 hours. At 4 hours, the
media was removed and replaced with standard TR-MCF7 media
containing 10 mM 4-OHT or 95% EtOH, the vehicle for 4-OHT, for
44 hours. After 48 hours from initial treatment, media were collected
and analyzed by LDH assay. Values shown are a % of vehicle treatment
6 SD (B).
doi:10.1371/journal.pone.0035566.g003
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35566Figure 4. Brief exposure to YM-1 restores tamoxifen effect in resistant cell model. TR-MCF7 cells were treated with 4-OHT for 48 hours,
YM-1 (or vehicle) for 4 hours followed by 44 hours of either 4-OHT or 95% EtOH, or YM-1 (or vehicle) for 48 hours. At 48 hours from initial treatment,
MTT viability assays were performed. Viability values of each treatment as a % of 48 hours of 4-OHT treatment 6 SD (A). 2-Way ANOVA analysis
comparing all YM-1 treatment groups (Gray squares- 4-hour YM-1then 4-OHT, open diamonds- 48 hour YM-1, black triangles- 4-hour YM-1 then 95%
EtOH), revealed significance across concentrations (F(2,30)=54.22, p,0.0001), and treatment strategy (F(4, 30)=41.04, p,0.0001), but no significant
interaction (F(8,30)=1.83, p=0.1107). * - indicates significant difference (p,0.05) of 4-hour YM-1 then 4-OHT from other two groups with exception
of 10 mM treatments, significance as indicated (ns=p.0.05)(B). 1-way ANOVA of YM-1+4-OHT strategy revealing significance of 10 mM concentration
(F(4,10)=16.49, p=0.0002)(C). Analysis of YM-1+95% EtOH, by 1-way ANOVA, revealed no significance across tested concentrations (F(4,10)=3.435,
p=0.0516)(D). 48-hour YM-1 treatment showed significance differences between all concentrations and the 10 mM concentration, by 1-way ANOVA
(F(4,10)=12.32, p=0.0007)(E). 1-way ANOVA analysis (F,(5,12)=24.33, p,0.0001) comparing all 10 mM YM-1 treatments, 48-hour 4-OHT, and vehicle
treatments revealed no significant difference between 48-hour 4-OHT and both 4-hour 10 mM YM-1+95% EtOH and 48-hour 10 mM YM-1 treatments;
whereas the 48-hour 4-OHT and the 4-hour 10 mM YM-1+95% EtOH were significantly different from the 4-hour YM-1+4-OHT treatment (p,0.05)(F).
doi:10.1371/journal.pone.0035566.g004
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treatment and vehicle treatments as separate groups, were
analyzed by one-way ANOVA (F,(5,12)=24.33, p,0.0001).
Tukey’s post-hoc test revealed that 4 hour YM-1 followed by 4-
OHT was significantly different from the 4-OHT 48 hours
treatment (p,0.05), whereas both the 48 hour 10 mM YM-1
and the 4 hour 10 mM YM-1 followed by 95% EtOH treatments
were not significantly significant from the 4-OHT 48 hour
treatment (Figure 4F). This analysis also displayed that 10 mM
YM1 followed by 4-OHT is significantly different from 10 mM
YM1 followed by 95% EtOH (p,0.05).
These findings suggested that just a 4 hour treatment of 10 mM
YM-1 could re-sensitize TR-MCF7 cells to tamoxifen/4-OHT,
stopping cell growth without causing overt toxicity. The potential
mechanisms for this phenomenon were then explored. One
plausible mechanism was aberrant kinase activity, which is known
to promote tamoxifen resistance by phosphorylating ERa at a site
known to promote estrogen independent activity [14,15,16,17,18].
We treated TR-MCF7 cells as described for the experiments in
Figure 4A & B. Nuclear proteins were isolated and probed for
levels of ERa pS167, a site that when phosphorylated conveys
tamoxifen independence. Indeed, phosphorylation of ERa pS167
was elevated in the presence of 4-OHT; however, the addition of
10 mM YM-1 abrogated this event (Figure 5A & B). YM-1 did
not alter the nuclear localization of ERa into the nucleus
(Figure 5C & D).
S167 of ERa falls is contained within an Akt (Akt/PKB)
consensus site. Akt is a pro-survival kinase with two isoforms
known to interact with ERa. We treated MCF7 cells with 10 mM
YM-1 for 6 hours to avoid toxicity and looked for changes in
either Akt levels or activation. The levels of Akt1 and Akt2 were
dose dependently reduced by YM-1 (Figure 6A & B). This
suggests that YM-1 can cause toxicity specific to cancer cells,
similar to the parent compound MKT-077, but that YM-1 does so
by reducing pro-survival kinases like Akt, potentially leading to
alterations in resistance mechanisms in refractory tumors. This
data agrees with work previous work demonstrating that the effects
of LY294002, an inhibitor of the PI3K/Akt signaling pathway
inhibitor, on tamoxifen-induced apoptosis were specific for
inhibiting Akt activity [16].
Discussion
Here we describe the therapeutic potential of an MKT-077
derivative, YM-1. This compound, similar to MKT-077, was
specifically toxic to cancer cells. YM-1 also had greater efficacy
and cytosolic localization than MKT-077. Brief exposure to YM-1
was able to re-sensitize refractory breast cancer cells to tamoxifen,
a common therapy used in the clinic. This mechanism was shown
to be Akt dependent as YM-1 was able to reduce Akt levels as well
as the phosphorylation of ERa at an Akt consensus site. These
data demonstrate the potential for rhodacyanine derivatives in the
treatment of refractory cancers.
Figure 5. Phosphorylation but not localization of Estrogen Receptor a altered by YM-1. TR-MCF7 cells were treated with indicated
conditions for 4 hours. Nuclear isolates and cytosolic fractions were compared by Western blot, representative blots shown (A & C). Densitometry
analysis of pERa and ERa levels displayed as % of vehicle treatment 6 SD (B & D).
doi:10.1371/journal.pone.0035566.g005
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mitochondrial of MKT-077, drives the increased toxicity and Akt
clearance observe with YM-1. Though the mitochondrial aspects
of MKT-077 are well characterized [1,2,3], recent data suggests
that MKT-077 can also interact with cytosolic Hsp70 family
members [22]. If MKT-077 is able to inhibit cytosolic Hsp70 as it
does mortalin [4,5], YM-1 might also inhibit cytosolic Hsp70.
Hsp70 inhibitors have demonstrated cancer specificity as well as
the ability to reduce Hsp70 client proteins [20,23,24,25]. We
suspect that Hsp70 inhibition could be the mechanism of YM-1;
however further examination is required.
Tamoxifen therapies typically fail due to the development of
resistance. Acquired resistances take time to develop. Our studies
have demonstrated that brief treatments with YM-1 can re-
sensitize refractory cancers to tamoxifen. The benefit of such a
short treatment is the lack of opportunity for a resistance to YM-1
itself as well as reduced likelihood for off-target toxicities.
Moreover, the ability to negate existing resistances allows for the
reintroduction of putative chemotherapies; preventing the need for
more costly and potentially dangerous secondary and tertiary
therapeutic strategies. In addition, YM-1 treatment alone was able
to selectively kill only certain cancer cells, suggesting not only
tolerability to the approach but also a need for further
characterization about the specific cell types that might be
sensitive to these compounds and Akt depletion. These benefits
to patients coupled with the high number of cancer varieties linked
to Akt dysfunction provides a platform for the continued study and
development of new compounds to deplete Akt through
manipulation of the rhodocyanine scaffold.
While other kinases have been identified to phosphorylated
ERa, Akt is a major survival kinase, regardless of resistance
phenotype, and its clearance could enhance the efficacy of
chemotherapeutics. If our hypothesis that YM-1 is an Hsp70
inhibitor is accurate, this clearance could be due to enhanced
ubiquitination of Akt, as the ubiquitin ligase for Akt, CHIP
(carboxy terminus of Hsc70 interacting protein) [26], is known to
interact with Hsp70 [27].
These studies demonstrate the need for more mechanistic
insight into the mode of action of rhodacyanines. Minor changes
between MKT-077 and YM-1 lead to an increased cytosolic
presence that was able to maintain similar specificity. This suggests
that modifications to this scaffold could elicit specific toxicity or
reduce renal toxicity, as observed in the clinical and laboratory
trials [1,2,3]. In fact, our data demonstrating an almost
preferential killing of breast cancer cells, versus other cancer cell
types, suggests that specificity for particular tumor varieties could
be built into the rhodacyanine scaffold.
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